Marcén R, Galeano C, Fernandez-Rodriguez A, Jiménez S, Teruel J L, Burgos F J, Quereda C
Department of Nephrology, Hospital Ramón y Cajal, Madrid, Spain.
Transplant Proc. 2012 Nov;44(9):2593-5. doi: 10.1016/j.transproceed.2012.09.033.
Anemia, a common complication after kidney transplantation, has a controversial impact on graft or patient survivals or the appearance of cardiovascular disease. The present study investigated the incidence and risk factors for anemia in the first year after transplantation and its effects on graft and patient outcomes.
Among 389 patients transplanted between January 2000 and June 2008, the 331 with functioning grafts at 1 year were included in the study. The mean follow-up was 84 ± 31.8 months. Anemia was defined according to the World Health Organization as a hemoglobin < 13 g/dL in men and < 12 g/dL in women.
The 88 patients (26.6%) with anemia included 21 (6.3%) who were receiving erythropoiesis stimulant agents. The predictive factors for anemia were: initial immunosuppression with cyclosporine (odds ratio [OR] 2.08, 95% confidence interval [CI] 1.25-3.47; P = .005), serum creatinine (mg/dL) at discharge (OR 1.7; CI 95% 1.26-2.15 P = .000), and 1-year serum albumin (g/dL; OR 0.21; CI 95% 0.10-0.71 P = .001). Donor age in years (OR 1.02; CI 95% 1.00-1.03, P = .054) was close to significance. Cox multivariate analysis showed 1-year hemoglobin (g/dL) to be associated with graft (hazard ratio [HR] 0.81, 95% CI 0.69-0.96, P = .003) and patient survivals after adjusting for other variables (HR 0.74; 95% CI 0-59-0.96, P = .023). But it was only a cardiovascular risk factor when serum creatinine was not included in the model.
Approximately one quarter of patients with functioning grafts show anemia at 1-year. Graft function, initial immunosuppression, serum albumin, and perhaps donor age were risk factors for anemia, which had a negative impact on graft and patient survival, and could be a risk factor for cardiovascular disease.
贫血是肾移植后常见的并发症,对移植肾或患者存活以及心血管疾病的发生有争议性影响。本研究调查了移植后第一年贫血的发生率、危险因素及其对移植肾和患者预后的影响。
在2000年1月至2008年6月间接受移植的389例患者中,纳入了1年后移植肾功能良好的331例患者。平均随访时间为84±31.8个月。根据世界卫生组织的定义,贫血为男性血红蛋白<13 g/dL,女性血红蛋白<12 g/dL。
88例(26.6%)贫血患者中,21例(6.3%)正在接受促红细胞生成素刺激剂治疗。贫血的预测因素为:初始使用环孢素进行免疫抑制(比值比[OR]2.08,95%置信区间[CI]1.25 - 3.47;P = 0.005)、出院时血清肌酐(mg/dL)(OR 1.7;95%CI 1.26 - 2.15,P = 0.000)以及1年时血清白蛋白(g/dL;OR 0.21;95%CI 0.10 - 0.71,P = 0.001)。供者年龄(岁)(OR 1.02;95%CI 1.00 - 1.03,P = 0.054)接近具有统计学意义。Cox多因素分析显示,在调整其他变量后,1年时血红蛋白(g/dL)与移植肾存活(风险比[HR]0.81,95%CI 0.69 - 0.96,P = 0.003)和患者存活相关(HR 0.74;95%CI 0.59 - 0.96,P = 0.023)。但仅在模型中未纳入血清肌酐时,它才是心血管危险因素。
约四分之一移植肾功能良好的患者在1年时出现贫血。移植肾功能、初始免疫抑制、血清白蛋白以及可能的供者年龄是贫血的危险因素,贫血对移植肾和患者存活有负面影响,并且可能是心血管疾病的危险因素。